Acotec-B (06669) released its fifth Environmental, Social and Governance Report, detailing significant gains in innovation output, operational governance and environmental performance for the year ended 31 December 2025.
R&D AND PRODUCT PIPELINE • The medical-technology group added 11 new regulatory-approved products, lifting the commercial portfolio to 32 items across vascular surgery, cardiology, nephrology, neurology and oncology. • Breakthroughs include the Vertebral Artery DCB (AcoArt Verbena®) and the Sirolimus-Coated Coronary Balloon (AcoArt Canna®), while the Peripheral Radiofrequency Ablation System secured US FDA 510(k) clearance. • R&D strength was supported by 145 dedicated staff and 87 in-house training sessions. Intellectual-property assets rose to 336 registered or pending rights.
GLOBAL EXPANSION & MARKET ACCESS • Partnership with Boston Scientific enabled sales of Acotec devices in 17 countries; a renewed three-year framework agreement begins 1 January 2026. • In China, coverage extended to more than 3,000 hospitals, backed by over 300 academic and patient-education events.
GOVERNANCE & WORKFORCE • The seven-member board counts four women, exceeding 50% female representation. • All 653 employees received training, averaging 23.53 hours domestically; 61% of staff are women. • Lost-time injuries remained at zero, marking 4.9 million consecutive safe working hours since 2021. • Eleven anti-fraud and ethics sessions achieved 100% employee coverage.
ENVIRONMENTAL METRICS • Total greenhouse-gas emissions were 6,126.74 tCO₂-e, comprising 100.94 tCO₂-e (Scope 1) and 6,025.80 tCO₂-e (Scope 2). • Electricity use reached 8.43 million kWh, while water consumption totalled 29,906 m³. • Hazardous-waste generation stood at 28.45 tonnes; wastewater discharge measured 26,037 m³, both fully compliant with local standards. • Energy-saving retrofits to clean-room HVAC systems and weekend shutdowns of chillers were key reduction measures.
COMMUNITY & ACCESSIBLE HEALTHCARE • Free-clinic initiatives and vascular-health outreach benefited over 400 residents; distributor and clinician training exceeded 50 sessions to promote standardised treatment at grassroots level.
LOOKING AHEAD The board confirms that product-quality management, R&D innovation and IP protection remain top ESG priorities and that governance, environmental stewardship and responsible supply-chain practices will continue to be strengthened in 2026.